

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**

Summary of Main Points from the Meeting held on the 8th April 2013

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the March 2013 meeting were approved and will be circulated.

3. Matters Arising

The Committee noted the matters arising from the previous meeting.

4. New Medicines Applications

Additions:

Insulin Degludec injection

Decision: Approved. Tariff Included Medicine

Insulin Degludec is an ultra-long-acting insulin analogue. It has been approved for use in the following circumstances:

- Frequent or disabling hypoglycaemic episodes on basal analogue insulins
- Work shift patterns where regular eating patterns and insulin administration is not possible e.g. night shifts
- Patients who need twice daily basal analogue insulin to maintain blood glucose control but cannot receive twice daily injections due to needle phobia or third party administration
- Type 1 DM patients who have recurrent nocturnal hypoglycaemia and are waiting for approval for s/c insulin pump therapy
- T2DM patients who take U500 (unlicensed) insulin where switching to a licensed product more concentrated than standard insulin e.g. degludec 200units/ml

This is limited to consultant initiation. An application will be made to NWLIF panel.

Tadalafil 5mg Tablets

Decision: Declined.

Tadalafil 5mg tablets are indicated for treatment of the signs and symptoms of BPH in adult patients. This was declined on the grounds that NICE is currently unable to recommend the use of tadalafil in the NHS for the treatment of symptoms associated with benign prostatic hyperplasia because there is insufficient evidence available to be able to undertake the appropriate analysis required to estimate the cost effectiveness of tadalafil. If this situation should change in the future the Committee would welcome an updated submission.

LAT[®] Gel

Decision: Approved. Tariff Included Medicine

LAT[®] Gel is indicated for use as topical local anaesthetic in wound cleaning, exploration and closure in paediatric patients to reduce the need for needle infiltration of lidocaine and hence associated anxiety and pain in paediatric patients. It may also reduce the need for general anaesthesia.

Voractiv[®] Tablets. Tariff Included Medicine

Decision: Approved. Tariff Included Medicine.

Voractiv[®] is indicated as a quadruple combination preparation (rifampicin, isoniazid, pyrazinamide and ethambutol) in the treatment of Tuberculosis.

Ex-panel

- **Lenograstim 105mcg and 263mcg Injection (Vials) (Approved)**
For the management of neutropenic sepsis in paediatric POSCU patients. The vials enable easier administration compared with the pre-filled syringes.
- **Liquiband Optima[®] Tissue Glue (Approved)**
Easier to handle device and is more precise than the Flow Control[®]. There causes less sting which is beneficial as it will be used around eye area. There have been 2 incidents where a child's eye was inadvertently sealed. It is hoped that Optima[®] will minimise reoccurrence.
- **Co-trimoxazole 480mg injection (Approved)**
960mg injection is included on the formulary. 480mg injection to be added for paediatric patients.
- **Simeticone 40mg/ml (Infacol[®]) (Approved)**
Used in Endoscopy to help break down bubbles of air in the GI tract for better visibility during capsule endoscopy.
- **Propranolol 1mg/ml liquid (Approved)**
Tablets are included on the formulary. Liquid to be added for paediatrics and patients with swallowing difficulties or NG / PEG tubes
- **Mycophenolate mofetil 1g/5ml liquid (Approved)**
Tablets are included on the formulary. Liquid to be added for paediatrics and patients with swallowing difficulties or NG / PEG tubes

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**

- **Venos® Honey and Lemon syrup (Approved)**
Only for CNWL (Max Glatt Ward) as an alcohol free preparation for the management of cough.
- **Bradford slings (Deferred to next month)**
Non-medicinal product/device. Insufficient information submitted in relation to this request. Deferred until next month.

5. NICE Guidance on developing and updating local formularies

NICE Guidance on developing and updating local formularies

Decision: Noted

A status report was provided on the updated action plan as at March 2013.

Formulary upload published on the Trust internet website

A status report was provided on the Trust formulary which is now published on the Trust internet website.

Trust Medicine Policy - Section 19. The formulary

Decision: Approved

Updated to include that the Trust formulary is now published on the Trust internet website

6. NICE Guidance

Nice Guidance March 2013

- **TA274 – Ranibizumab for diabetic macular oedema**

Ranibizumab is recommended as an option for treating visual impairment due to diabetic macular oedema only if:

- the eye has a central retinal thickness of 400 micrometres or more at the start of treatment **and**
- the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).

- **TA275 – Apixaban for the preventing stroke in non-valvular atrial fibrillation**

Apixaban is recommended as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with non-valvular atrial fibrillation with 1 or more risk factors such as:

- prior stroke or transient ischaemic attack
- age 75 years or older
- hypertension
- diabetes mellitus
- symptomatic heart failure

The Committee noted NICE guidance 274.

The Committee approved the addition of apixaban to the Trust formulary in line with NICE Guidance 275.

7. IVIG Update

The panel noted the IVIG report.

There were 13 IVIG issues in March 2013, with 8 new requests.

8. Items for Noting

- **2012-2013 Medicines Related CQUINs Performance Report: NWL Integrated Formulary Adherence Quarter 3 results**

Noted. The compliance rate for February 2013 was 93%. An audit of all issues on out-patient and discharge prescriptions was undertaken rather than a 1% sample audit on the request of the commissioners. The result is a “worst case scenario” as all non-compliant issues were assumed to be initiated by the Trust and intended for the GP to continue. This explains why the results are lower when compared with previous months.

- **2012-13 Medicines Related CQUINs Performance Report: Medicines Reconciliation**

Noted. The compliance rate for March 2013 was 66%. The target of 65% was therefore achieved but not the stretch target of 70%

- **CD Quarterly report - Q3 2012/13**

Noted

- **CD Occurrence Report Q3 2012/13 (with addendum)**

Noted

- **Drugs Sub-Committee meeting minutes: Feb 2013**

Noted

- **Category A & B unlicensed medicinal products**

Noted

- **MHRA Drug Safety Update: Mar 2013**

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**

Noted

- **BNF update: Feb 2013**

Noted. New edition of the BNF No. 65 now available and will be distributed soon.

9. Papers to go to the Trust Quality Committee

The following papers should be sent to the Trust Quality Committee:

- Medicines Committee Summary Notes – March 2013
- CD Quarterly report - Q3 2012/13
- CD Occurrence Report Q3 2012/13 (with addendum)

10. AOB

The Trust Medicines Policy has been update in line with the Trust procedure for writing policies & procedures and is now compliant with NHSLA Level 3 Document Management standards.

1. Cathy Mooney will act as the approving executive
2. All documents are in PDF format
3. All documents are saved as controlled documents

11. Date of the next meeting

Monday 13th May 2013, 8.00 – 9.00 Boardroom, Lower Ground Floor.

Closing date for papers: Friday 19^h April 2013